10-Q · May 15, 2026
Indaptus Therapeutics reported a narrower net loss of $2.5 million for Q1 2026, an improvement from $4.5 million in Q1 2025. The company significantly reduced its loss per share from $9.11 to $0.23, driven by an 83%…
Earnings analysis · 10-Q
INDP earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The 10-Q does not provide revenue, margin, cash-flow, segment, or EPS figures in the supplied filing text, and it provides no quantitative guidance. The Company strengthened liquidity through a 20,000,000-share private…
Read full summary
The 10-Q does not provide revenue, margin, cash-flow, segment, or EPS figures in the supplied filing text, and it provides no quantitative guidance. The Company strengthened liquidity through a 20,000,000-share private placement generating approximately $12.0 million, but has no active clinical development programs and continues to evaluate strategic alternatives. Executive turnover and the possibility of further operating reductions, restructuring, or a wind-down make the overall outlook bearish.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$12.0 million private placement completed
The Company completed a private placement of 20,000,000 common shares at $0.60 per share on June 17, 2026, generating approximately $12.0 million of gross proceeds.
-
Controls remained effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
-
No material control changes
The filing states that there were no changes during the six months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Strategic asset evaluation expanded
The Company appointed Joe Z. Tsien as a scientific consultant in April 2026 to evaluate research and data-related initiatives, including sleep-related biological signals and neurophysiological activity patterns.
What to watch
-
No active clinical development programs
As of the filing date, the Company had discontinued further enrollment in its combination study, had no participants remaining in any ongoing Decoy20 clinical study, and had no active clinical development programs.
-
Strategic direction remains uncertain
The Company stated that it has not determined which, if any, strategic alternatives or initiatives it will pursue. It warned that failure to secure financing or identify a viable direction could lead to further operating reductions, restructuring, a wind-down, or bankruptcy protection.
-
Executive turnover adds transition risk
Executive-management turnover may disrupt operations and strategic initiatives: David E. Lazar and Jeffrey Meckler resigned from executive officer positions after March 23, 2026 transactions, and Chief Scientific Officer Michael Newman resigned on April 16, 2026.
-
Additional financing may be required
The Company substantially reduced Decoy20 development activities pending additional financing, strategic review, or other developments, despite raising approximately $12.0 million through the June 17, 2026 private placement.
Management's outlook
No quantitative revenue or EPS outlook was provided in the filing. Management is evaluating strategic alternatives, but did not provide financial guidance.
Earlier filings 4
10-K · March 17, 2026
Indaptus Therapeutics is a clinical-stage immunotherapy company with no ongoing clinical enrollment and no current plans to start new trials; its 2025 year-end filing centers on a December 2025 $6.0 million…
10-K · March 13, 2025
Indaptus Therapeutics is a clinical-stage biotech developing Decoy20, a systemically administered, killed Gram-negative bacterial immunotherapy. The 10-K highlights Phase 1 progress (single-dose and weekly-dosing…
10-Q · November 12, 2024
Indaptus reported Q3 (three months ended September 30, 2024) GAAP net loss of $3,069,036 (EPS of $(0.32)), an improvement versus prior-year Q3 net loss of $3,922,388 (EPS $(0.47)). Operating expenses declined to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.